Last reviewed · How we verify
MEDI8897 50 mg
At a glance
| Generic name | MEDI8897 50 mg |
|---|---|
| Sponsor | MedImmune LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Upper respiratory tract infection
- Anaemia
- Gastroenteritis
- Otitis media
- Cough
- Pyrexia
- Lower respiratory tract infection
- Rhinorrhoea
- Dry skin
- Eczema
- Diarrhoea
- Impetigo
Key clinical trials
- Evaluate the Safety and Efficacy of Nirsevimab in Healthy Preterm and Term Infants in China (PHASE3)
- A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab (PHASE3)
- Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children (PHASE2)
- A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. (PHASE2)
- A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |